

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																
NATURE OF CONVEYANCE:	SECURITY INTEREST																
CONVEYING PARTY DATA																	
<table border="1"> <thead> <tr> <th>Name</th> <th>Formerly</th> <th>Execution Date</th> <th>Entity Type</th> </tr> </thead> <tbody> <tr> <td>Amarin Pharmaceuticals Ireland Limited</td> <td></td> <td>12/19/2012</td> <td>COMPANY: IRELAND</td> </tr> </tbody> </table>				Name	Formerly	Execution Date	Entity Type	Amarin Pharmaceuticals Ireland Limited		12/19/2012	COMPANY: IRELAND						
Name	Formerly	Execution Date	Entity Type														
Amarin Pharmaceuticals Ireland Limited		12/19/2012	COMPANY: IRELAND														
RECEIVING PARTY DATA																	
<table border="1"> <tr> <td>Name:</td> <td>BioPharma Secured Debt Fund II Holdings Cayman LP</td> </tr> <tr> <td>Street Address:</td> <td>Walker House, 87 Mary Street</td> </tr> <tr> <td>Internal Address:</td> <td>c/o Walkers Corporate Services Limited</td> </tr> <tr> <td>City:</td> <td>George Town, Grand Cayman</td> </tr> <tr> <td>State/Country:</td> <td>CAYMAN ISLANDS</td> </tr> <tr> <td>Postal Code:</td> <td>KY1-9005</td> </tr> <tr> <td>Entity Type:</td> <td>CORPORATION: CAYMAN ISLANDS</td> </tr> </table>				Name:	BioPharma Secured Debt Fund II Holdings Cayman LP	Street Address:	Walker House, 87 Mary Street	Internal Address:	c/o Walkers Corporate Services Limited	City:	George Town, Grand Cayman	State/Country:	CAYMAN ISLANDS	Postal Code:	KY1-9005	Entity Type:	CORPORATION: CAYMAN ISLANDS
Name:	BioPharma Secured Debt Fund II Holdings Cayman LP																
Street Address:	Walker House, 87 Mary Street																
Internal Address:	c/o Walkers Corporate Services Limited																
City:	George Town, Grand Cayman																
State/Country:	CAYMAN ISLANDS																
Postal Code:	KY1-9005																
Entity Type:	CORPORATION: CAYMAN ISLANDS																
PROPERTY NUMBERS Total: 2																	
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> <th>Word Mark</th> </tr> </thead> <tbody> <tr> <td>Registration Number:</td> <td>4238272</td> <td>VASCEPA</td> </tr> <tr> <td>Serial Number:</td> <td>85764517</td> <td>V VASCEPA</td> </tr> </tbody> </table>				Property Type	Number	Word Mark	Registration Number:	4238272	VASCEPA	Serial Number:	85764517	V VASCEPA					
Property Type	Number	Word Mark															
Registration Number:	4238272	VASCEPA															
Serial Number:	85764517	V VASCEPA															
CORRESPONDENCE DATA																	
<p>Fax Number: 2028874288 <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i></p> <p>Phone: 202-887-4103 Email: lgeyer@akingump.com Correspondent Name: Laura Talley Geyer Address Line 1: 1333 New Hampshire Ave. NW Address Line 4: Washington, DISTRICT OF COLUMBIA 20036</p>																	
ATTORNEY DOCKET NUMBER:	687747.0015																
DOMESTIC REPRESENTATIVE																	

CH \$65.00 4238272

Name:
Address Line 1:
Address Line 2:
Address Line 3:
Address Line 4:

NAME OF SUBMITTER:	Laura Talley Geyer
Signature:	/Laura Talley Geyer/
Date:	12/19/2012

Total Attachments: 17

source=PSA_20121218_161337959 pdf#page1.tif
source=PSA_20121218_161337959 pdf#page2.tif
source=PSA_20121218_161337959 pdf#page3.tif
source=PSA_20121218_161337959 pdf#page4.tif
source=PSA_20121218_161337959 pdf#page5.tif
source=PSA_20121218_161337959 pdf#page6.tif
source=PSA_20121218_161337959 pdf#page7.tif
source=PSA_20121218_161337959 pdf#page8.tif
source=PSA_20121218_161337959 pdf#page9.tif
source=PSA_20121218_161337959 pdf#page10.tif
source=PSA_20121218_161337959 pdf#page11.tif
source=PSA_20121218_161337959 pdf#page12.tif
source=PSA_20121218_161337959 pdf#page13.tif
source=PSA_20121218_161337959 pdf#page14.tif
source=PSA_20121218_161337959 pdf#page15.tif
source=PSA_20121218_161337959 pdf#page16.tif
source=PSA_20121218_161337959 pdf#page17.tif

PATENT SECURITY AGREEMENT

This Patent Security Agreement (the "Security Agreement") is made the 19th day of December, 2012, by and between **AMARIN PHARMACEUTICALS IRELAND LIMITED**, a company incorporated under the laws of Ireland (registered number 408912) having its registered office at 88 Harcourt Street, Dublin 2, and its permitted successors and assigns (the "Grantor") and **BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP**, a Cayman Islands exempted limited partnership, and its permitted successors and assigns (the "Secured Party").

RECITALS

WHEREAS, reference is made to that certain Purchase and Sale Agreement ("the Agreement") dated as of December 6, 2012 (and as amended, supplemented, restated, or otherwise modified from time to time), by and between the Grantor, the Secured Party and Amarin Corporation PLC, a public limited company incorporated under the laws of England and Wales, and its permitted successors and assigns;

WHEREAS, pursuant to the Agreement, the Grantor granted to the Secured Party a security interest in regards to all of Grantor's right, title, and interest in, to, and under the Additional Collateral, whether now owned or hereafter acquired by the Grantor and all of Grantor's rights and privileges with respect thereto;

WHEREAS the Grantor and the Secured Party have agreed to execute all documents to perfect the security interest of the Secured Party in such Additional Collateral of the Grantor, perfected and prior to all other Encumbrances thereon;

WHEREAS, in connection with the Agreement, the Grantor and the Secured Party have entered into this Security Agreement as of the date hereof (and as amended, supplemented, restated, or otherwise modified from time to time);

WHEREAS, the Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Party with respect to the security interest in the Additional Collateral granted hereby are more fully set forth in the Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

WHEREAS, as a condition, among others, to the terms contemplated by the Agreement in regards to the Additional Collateral, the parties hereto execute this Security Agreement.

NOW THEREFORE, the parties hereto agree as follows:

1. Defined Terms. All capitalized terms used but not otherwise defined herein have the meanings ascribed to them, or incorporated by reference in, the Agreement.
2. Grant of Security Interest. Pursuant to the terms of the Agreement, Grantor hereby grants a security interest in all of its right, title, and interest in, to, and under all of the following Additional Collateral:

(a) all Vascepa Product Rights set forth on Exhibit A to this Security Agreement and all of Grantor's rights and privileges with respect thereto;

(b) all Regulatory Approvals;

(c) all Supporting Obligations (as such term is defined in the UCC) in respect of the foregoing and all collateral security and guarantees given by any Person with respect to any of the foregoing;

(d) all of Grantor's books and records relating to any and all of the foregoing; and

(e) all Proceeds (as such term is defined in the UCC) and products of and to any and all of the foregoing.

3. Reference to the Agreement. This Security Agreement has been entered into by the Grantor and the Secured Party solely for purposes as contemplated by the Agreement. In the event of any inconsistency between any of the terms or provisions hereof and the terms and provisions of the Agreement, the terms and provisions of this Security Agreement shall govern.

4. Termination. At the end of the Term, the Secured Party shall execute, acknowledge and deliver to the Grantor an instrument in writing in recordable form releasing the collateral pledge, grant, assignment, lien and security interest in the Additional Collateral, including the Vascepa Product Rights under this Security Agreement.

5. Counterparts. This Agreement may be executed in two or more counterparts, each of which will be an original, but all of which together will constitute one and the same instrument. To evidence the fact that it has executed this Agreement, a Party may send a copy of its executed counterpart to the other Parties by facsimile or other electronic transmission. In such event, such Party will forthwith deliver to the other Parties the counterpart of this Agreement executed by such Party.

6. Governing Law. This Security Agreement shall be construed in accordance with and governed by the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.

[Signature page follows]

IN WITNESS WHEREOF, the Secured Party and the Grantor have caused this Agreement to be duly executed by their respective officers thereunto duly authorized, as of the day and year first set forth above.

**BIOPHARMA SECURED DEBT FUND II HOLDINGS
CAYMAN LP** as the Secured Party

By: Pharmakon Advisors, LP, its investment
manager

By: _____

Name: _____

Title: _____

PRESENT when the **COMMON SEAL**

of **AMARIN PHARMACEUTICALS IRELAND
LIMITED**, as Grantor

was affixed hereto:

By: Patrick J. Auld

Title: Director


By: [Signature]

Title: Director/Secretary

IN WITNESS WHEREOF, the Secured Party and the Grantor have caused this Agreement to be duly executed by their respective officers thereunto duly authorized, as of the day and year first set forth above.

**BIOPHARMA SECURED DEBT FUND II HOLDINGS
CAYMAN LP as the Secured Party**

By: Pharmakon Advisors, LP, its investment
manager

By: 
Name: Pedro Gonzalez de Cosu
Title: Managing Member

PRESENT when the COMMON SEAL

**of AMARIN PHARMACEUTICALS IRELAND
LIMITED, as Grantor**

was affixed hereto:

By: _____
Title: Director

By: _____
Title: Director/Secretary

EXHIBIT A

VASCEPA PRODUCT RIGHTS

“**Vascepa Patent Rights**” means (i) the Patents and patent applications listed in Schedule I below (including any PCT and/or U.S. utility application claiming priority to such provisional application(s) that are filed on or before the one year conversion date of such application(s)); (ii) any patent or patent application that claims priority to, and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of, any patent application identified in (i); (iii) any patents issuing on any patent application identified in (i) or (ii), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (iv) any claim of a divisional, continuation or continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (i), (ii) or (iii); (v) any foreign counterpart (including PCTs) of any patent or patent application identified in (i), (ii) or (iii) or of the claims identified in (iv); and (vi) any supplementary protection certificates or similar patent term extensions of any patents and patent applications identified in (i) through (v).

“**Vascepa Product Rights**” means any and all of the following, as they exist throughout the world: (A) Vascepa Patent Rights; (B) rights in registered and unregistered trademarks, service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names, and registrations and applications for registration of any of the foregoing, in each case, as related to a Product including, but not limited to, those trademarks listed on Schedule II attached hereto; (C) copyrights in both published and unpublished works, including without limitation all compilations, databases and computer programs, manuals and other documentation and all copyright registrations and applications, and all derivatives, translations, adaptations and combinations of the above, in each case, as related to a Product; (D) rights in know-how, trade secrets, confidential or proprietary information, research in progress, algorithms, data, databases, data collections, designs, processes, procedures, methods, protocols, materials, formulae, drawings, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, and the results of experimentation and testing, including samples, in each case, as specifically related to a Product; (E) any and all other intellectual property rights and/or proprietary rights specifically relating to any of the foregoing; (F) claims of infringement and misappropriation against Third Parties relating to a Product; and (G) regulatory filings, submissions and approvals related to a Product, including, but not limited to, Vascepa New Drug Application No. N202057 and any supplemental New Drug Application relating thereto, and all data provided in any of the foregoing.

Schedule I

App'n No.	Jurisdiction	Publication No.	Patent No.
U.S. 09/893,473	United States	N/A	U.S. 6,479,544
U.S. 12/052,598	United States	U.S. 2008/0200547	U.S. 8,188,146
U.S. 12/951,620	United States	U.S. 2011/0065793	N/A
U.S. 13/439,392	United States	U.S. 2012/0195963	N/A
U.S. 61/093,506	United States	N/A	N/A
U.S. 13/061,865	United States	U.S. 2011/0236476	N/A
PCT/US09/55760	WIPO	WO 2010/028067	N/A
2009288066	Australia	AU2009288066 A1	N/A
09792186.0	Europe	EP 2334295 A1	N/A
11113816.2	Hong Kong	N/A	N/A
2011-526172	Japan	JP 2012501356 A	N/A
U.S. 61/151,291	United States	N/A	N/A
U.S. 61/173,755	United States	N/A	N/A
U.S. 12/702,889	United States	U.S. 2010/0311834	U.S. 8,293,727
U.S. 13/282,145	United States	U.S. 2012/0093924	U.S. 8,318,715
U.S. 13/284,408	United States	U.S. 2012/0039997	U.S. 8,314,086
U.S. 13/198,221	United States	U.S. 2011/0288171	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
U.S. 13/349,150	United States	U.S. 2012/0108663	U.S. 8,324,195
U.S. 13/349,153	United States	U.S. 2012/0108659	U.S. 8,293,728
U.S. 13/623,450	United States	N/A	N/A
U.S. 13/610,247	United States	N/A	N/A
U.S. 13/610,217	United States	N/A	N/A
U.S. 13/608,775	United States	N/A	N/A
U.S. 13/608,744	United States	N/A	N/A
U.S. 13/349,157	United States	U.S. 2012/0108660	N/A
U.S. 13/404,666	United States	U.S. 2012/0157530	N/A
U.S. 13/403,694	United States	U.S. 2012/0156285	N/A
U.S. 13/482,720	United States	U.S. 2012/0237594	N/A
PCT/US10/23638	WIPO	WO 2010/093634	N/A
PI10075186	Brazil	N/A	N/A
2751576	Canada	CA 2751576 A1	N/A
MX/a/2011/008448	Mexico	MX 2011008448 A	N/A
W-00201103156	Indonesia	N/A	N/A
1-2011-501498	Philippines	N/A	N/A
201105735-3	Singapore	SG 173612 A1	N/A
2010213899	Australia	AU 2010213899 A1	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
6081/CHENP/2011	India	N/A	N/A
10-2011-7019164	South Korea	KR 20110110321 A	N/A
594395	New Zealand	N/A	N/A
2011137415	Russia	N/A	N/A
2011/05612	South Africa	N/A	N/A
10704464.6	Europe	EP 2395991 A1	N/A
U.S. 61/173,763	United States	N/A	N/A
U.S. 12/769,885	United States	U.S. 2010/0278879	U.S. 8,298,554
U.S. 13/458,496	United States	U.S. 2012/0225120	N/A
U.S. 13/614,146	United States	N/A	N/A
U.S. 13/614,129	United States	N/A	N/A
U.S. 13/614,111	United States	N/A	N/A
U.S. 13/266,374	United States	U.S. 2012/0100208	N/A
PCT/US10/32952	WIPO	WO 2010/127103	N/A
PI1011876-4	Brazil	N/A	N/A
2759284	Canada	CA 2759284 A1	N/A
MX/a/2011/011538	Mexico	MX 2011011538 A	N/A
W-00201104224	Indonesia	N/A	N/A
1-2011-502196	Philippines	N/A	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
201107935-7	Singapore	SG 175389 A1	N/A
2010241571	Australia	AU 2010241571 A1	N/A
8167/CHENP/2011	India	N/A	N/A
10-2011-7026559	South Korea	KR 20120000109 A	N/A
595852	New Zealand	N/A	N/A
10770322.5	Europe	EP 2424356 A1	N/A
201080024932.X	China	CN 102458109 A	N/A
PI 2011005154	Malaysia	N/A	N/A
1101002913	Thailand	N/A	N/A
20110163902	Colombia	CO 6470838 A2	N/A
2011148362	Russia	N/A	N/A
2011/07699	South Africa	N/A	N/A
12106594.3	Hong Kong	N/A	N/A
U.S. 61/173,759	United States	N/A	N/A
U.S. 13/124,628	United States	U.S. 2012/0093922	N/A
U.S. 13/266,085	United States	U.S. 2012/0121698	N/A
U.S. 13/417,899	United States	U.S. 2012/0302589	N/A
U.S. 13/418,591	United States	U.S. 2012/0172432	N/A
PCT/US10/32948	WIPO	WO 2010/127099	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
P110144056	Brazil	N/A	N/A
2759176	Canada	CA 2759176 A1	N/A
MX/a/2011/011517	Mexico	MX 2011011517 A	N/A
W-00201104225	Indonesia	N/A	N/A
1-2011-502152	Philippines	N/A	N/A
201107941-5	Singapore	5G 175390 A1	N/A
2010241567	Australia	AU 2010241567 A1	N/A
8692/CHENP/2011	India	N/A	N/A
10-2011-7026224	South Korea	KR 20120089563 A	N/A
595789	New Zealand	N/A	N/A
2011148363	Russia	N/A	N/A
2011/07623	South Africa	N/A	N/A
10770320.9	Europe	EP 2424521 A2	N/A
201080019298.0	China	CN 102413825 A	N/A
PI 2011005155	Malaysia	N/A	N/A
1101002845	Thailand	N/A	N/A
11.163.910	Colombia	CO 6470839 A2	N/A
[PCT/US10/32948]	Chile	N/A	N/A
12108371.8	Hong Kong	N/A	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
12109460.8	Hong Kong	N/A	N/A
U.S. 13/540,319	United States	N/A	N/A
U.S. 61/187,132	United States	N/A	N/A
U.S. 12/815,569	United States	U.S. 2011/0034555	N/A
U.S. 13/272,520	United States	U.S. 2012/0035262	N/A
U.S. 13/359,114	United States	N/A	N/A
U.S. 13/404,686	United States	U.S. 2012/0157531	N/A
U.S. 13/403,699	United States	U.S. 2012/0232145	N/A
PCT/US10/38683	WIPO	WO 2010/147994	N/A
2010260129	Australia	AU 2010260129 A1	N/A
PI1011883-7	Brazil	N/A	N/A
2772378	Canada	CA 2772378 A1	N/A
201080035913.7	China	CN 102625847 A	N/A
12004609	Colombia	CO 6491035 A2	N/A
10790059.9	Europe	EP 2443246 A1	N/A
W-00201104652	Indonesia	N/A	N/A
358/CHENP/2012	India	N/A	N/A
10-2012-7000736	South Korea	KR 20120016677 A	N/A
MX/a/2011/013739	Mexico	MX 2011013739 A	N/A


App'n No.	Jurisdiction	Publication No.	Patent No.
PI2011006035	Malaysia	N/A	N/A
597193	New Zealand	N/A	N/A
1-2011-502583	Philippines	N/A	N/A
201109274-9	Singapore	SG 177254 A1	N/A
1101003657	Thailand	N/A	N/A
2012101275	Russia	N/A	N/A
2011/09211	South Africa	N/A	N/A
U.S. 61/723,108	United States	N/A	N/A
U.S. 61/245,086	United States	N/A	N/A
U.S. 12/888,994	United States	U.S. 2011/0071176	N/A
PCT/US10/50005	WIPO	WO 2011/038122	N/A
2010298222	Australia	AU 2010298222 A1	N/A
1120120066927	Brazil	N/A	N/A
2775339	Canada	CA 2775339 A1	N/A
10819462.2	Europe	EP 2480248 A1	N/A
W-00201201335	Indonesia	N/A	N/A
3314/DELNP/2012	India	N/A	N/A
10-2012-7009490	South Korea	KR 20120083408 A	N/A
MX/a/2012/003555	Mexico	MX 2012003555 A	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
1-2012-500596	Philippines	N/A	N/A
201202133-3	Singapore	N/A	N/A
2012/02263	South Africa	N/A	N/A
599061	New Zealand	N/A	N/A
2012116079	Russia	N/A	N/A
U.S. 61/655,879	United States	N/A	N/A
U.S. 61/310,443	United States	N/A	N/A
U.S. 13/040,977	United States	U.S. 2011/0218243	N/A
PCT/US11/27218	WIPO	WO 2011/109724	N/A
2011222544	Australia	AU 2011222544 A1	N/A
1120120223364	Brazil	N/A	N/A
2792090	Canada	CA 2792090 A1	N/A
11751431.5	Europe	N/A	N/A
W-00201203963	Indonesia	N/A	N/A
7652/DELNP/2012	India	N/A	N/A
[PCT/US11/27218]	Japan	N/A	N/A
10-2012-7024878	South Korea	N/A	N/A
MX/a/2012/010253	Mexico	N/A	N/A
602308	New Zealand	N/A	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
1-2012-501755	Philippines	N/A	N/A
2012142181	Russia	N/A	N/A
201206521-5	Singapore	N/A	N/A
2012/06706	South Africa	N/A	N/A
U.S. 61/417,691	United States	N/A	N/A
PCT/US11/62247	WIPO	WO 2012/074930	N/A
U.S. 61/477,001	United States	N/A	N/A
U.S. 61/650,058	United States	N/A	N/A
U.S. 61/556,573	United States	N/A	N/A
PCT/US12/63909	WIPO	N/A	N/A
U.S. 13/671,197	United States	N/A	N/A
U.S. 61/584,013	United States	N/A	N/A
U.S. 61/656,347	United States	N/A	N/A
U.S. 61/655,890	United States	N/A	N/A
U.S. 61/666,447	United States	N/A	N/A
U.S. 61/666,428	United States	N/A	N/A
U.S. 61/666,433	United States	N/A	N/A
U.S. 61/666,437	United States	N/A	N/A
U.S. 61/666,442	United States	N/A	N/A
U.S. 61/670,408	United States	N/A	N/A

App'n No.	Jurisdiction	Publication No.	Patent No.
U.S. 13/705,990	United States	N/A	N/A
U.S. 13/685,291	United States	N/A	N/A
U.S. 13/685,281	United States	N/A	N/A
U.S. 13/711,329	United States	N/A	N/A
U.S. 13/711,324	United States	N/A	N/A

Schedule II

Mark	Country	Owner Name	Application #	Registration #	Status	Classes	Goods Description
VASCEPA	RUSSIA	Amarin Pharmaceuticals Ireland Limited	2012710541		PENDING	05	05 - Pharmaceutical preparations for the treatment of cardiovascular conditions
VASCEPA	BRAZIL	Amarin Pharmaceuticals Ireland Limited	840084749		PENDING	05	05 - Pharmaceutical preparations for the treatment of cardiovascular conditions
VASCEPA	AUSTRALIA	Amarin Pharmaceuticals Ireland Limited	1484241		PENDING	05	05 - Pharmaceutical preparations for the treatment of cardiovascular conditions
VASCEPA	NEW ZEALAND	Amarin Pharmaceuticals Ireland Limited	956808		PENDING	05	05 - Pharmaceutical preparations for the treatment of cardiovascular conditions
VASCEPA	UNITED STATES	Amarin Pharmaceuticals Ireland Limited	85/202,744	4238272	REGISTERED	05	05 - Pharmaceutical preparations for the treatment of cardiovascular conditions
VASCEPA & Design	UNITED STATES	Amarin Pharmaceuticals Ireland Limited	85/764,517		PENDING	05	05 - Pharmaceutical preparations for the treatment of cardiovascular conditions
							
VASCEPA	EUROPEAN UNION (CTM)	Amarin Pharmaceuticals Ireland Limited	010203412	010203412	REGISTERED	05	05 - Pharmaceutical preparations for the treatment of cardiovascular conditions

									treatment of cardiovascular conditions
--	--	--	--	--	--	--	--	--	--